Cigna paying members to use biosimilars draws providers ire

Cigna pays members to switch to biological drugs that it says are clinically equivalent and cheaper—a new policy provoking objections from providers, who maintain that it crosses the line between covering medical expenses and practicing medicine—and that it threatens patients’ health.

Read the source article at Home | Modern Healthcare
2021-07-21 23:01:04